4 results
Approved WMOCompleted
The objective of this study is to evaluate the effect of the 4 successive monthly subcutaneous administrations of 30 mg of gevokizumab (in part A) , as well as 60mg (in part B) of the protocol, versus placebo on the reduction of arterial wall…
Approved WMOCompleted
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.
Approved WMOCompleted
This study aims to investigate the retina, macula and optic nerve head with Optical Coherence Tomography (OCT) in a cohort of AD patients in order to identify a neurodegenerative signature of AD consisting of neuroretinal degeneration, vascular…